Quarterly report [Sections 13 or 15(d)]

Common Stock Warrants and Options

v3.26.3
Common Stock Warrants and Options
9 Months Ended
Sep. 30, 2026
Common Stock Warrants And Options  
Common Stock Warrants and Options

Note 4 – Common Stock Warrants and Options

 

Common Stock Warrants

 

Common Stock warrant transactions for the nine months ended September 30, 2026 were as follows:

  

    Nine Months Ended September 30, 2026  
    Number of     Weighted Average  
    Warrants     Exercise Price  
Warrants outstanding at December 31, 2025     2,021,317     $ 23.00  
Granted     7,112,173       6.10  
Anti-dilution adjustment (1)     328,083       11.35  
Forfeited/cancelled     (6,886 )     1,054.00  
Exercised     (60,953 )     13.25  
Warrants outstanding at September 30, 2026     9,393,734     $ 8.34  
Warrants exercisable at September 30, 2026     2,543,280     $ 11.98  

 

(1) In connection with subsequent equity issuances, the exercise price of the warrants was reduced and the number of shares issuable upon exercise was increased in accordance with certain full-ratchet price and anti-dilution protection provisions of the warrant agreements.

 

 

The aggregate intrinsic value of all warrants outstanding and all warrants vested and exercisable as of September 30, 2026 was approximately $2,710,000 and $607,000, respectively, in each case based on the fair value of the Common Stock on September 30, 2026.

 

Pursuant to the May 2025 private placement of Series L Preferred Stock and 2025 Warrants, the Company issued an aggregate of 129,439 warrants to purchase shares of Common Stock with an initial exercise price of $51.075 per share, that are exercisable, subject to certain ownership limitations, immediately upon issuance and have a term of exercise equal to five years, as well as an aggregate of 470,256 warrants to purchase shares of Common Stock that vest upon the exercise of certain additional purchase rights with an initial exercise price of $51.075 per share, that are exercisable subject to certain vesting and ownership limitations, and have a term of exercise equal to five years from the date that the applicable warrant shares vest. The 2025 Warrants both have full-ratchet price and anti-dilution protections and are subject to other adjustments, as further described in the Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred Stock or the 2025 Warrants, as applicable, subject, solely with respect to adjustments in connection with the exercise of Greenshoe Rights, to a floor price of $11.35 per share (subject to adjustment for reverse and forward splits, recapitalizations and similar transactions). As of September 30, 2026, pursuant to full-ratchet price and anti-dilution protections the exercise price of the 2025 Warrants has been reduced to the floor price of $11.35. Since inception, the anti-dilution adjustment resulted in the 2025 Warrants being exercisable into an additional 2,029,507 shares of the Common Stock.

 

Pursuant to the September 2026 private placement of Series M Preferred Stock and 2026 Warrants, the Company issued an aggregate of 1,411,651 warrants to purchase shares of Common Stock with an initial exercise price of $6.10 per share, that are exercisable, subject to certain ownership limitations, immediately upon issuance and have a term of exercise equal to five years, as well as an aggregate of 5,684,522 warrants to purchase shares of Common Stock that vest upon the exercise of certain additional purchase rights with an initial exercise price of $6.10 per share, that are exercisable subject to certain vesting and ownership limitations, and have a term of exercise equal to five years from the date that the applicable warrant shares vest. The 2026 Warrants both have full-ratchet price and anti-dilution protections and are subject to other adjustments, as further described in the Series M Certificate of Designation or the 2026 Warrants, as applicable subject, solely with respect to adjustments in connection with the exercise of Greenshoe Rights. There will not be a floor price; provided, however, if the Company receives written notice from Nasdaq that a floor price should be implemented, the Series M Floor Price shall be set at $1.282, subject to adjustment for reverse and forward splits, recapitalizations and similar transactions. As of September 30, 2026, the exercise price of the 2026 Warrants remained at $6.10.

 

In April 2026, the Company issued pre-funded warrants underlying 16,000 shares of Common Stock with an aggregate fair value of $164,000 to a vendor as compensation for services. The warrants are exercisable at any time after issuance and until exercised in full.

 

Warrants outstanding as of September 30, 2026 are exercisable as follows:

  

      Warrants Outstanding and Exercisable as of September 30, 2026  

Range of

Exercise Price

   

Number

Outstanding

   

Weighted Average

Remaining Contractual Life (Years)

   

Weighted Average

Exercise Price

 
$ 0.0025       13,050       N/A     $ 0.0025  
  6.10       1,411,651       4.96       6.10  
  11.35       1,074,218       3.62       11.35  
  50.50       10,283       3.41       50.50  
  61.50       976       3.62       61.50  
  62.50       2,000       1.62       62.50  
  70.94       846       3.41       70.94  
  108.75       17,517       2.65       108.75  
  135.94       3,552       2.65       135.94  
  750.00       8,667       1.76       750.00  
  937.50       520       1.25       937.50  
          2,543,280       4.35       11.98  

 

 

Common Stock Options

 

In April 2022, the Company established the 2022 Omnibus Incentive Plan (the “Plan”) which established the maximum number of shares of Common Stock that may be issued pursuant to awards granted under the Plan at 6,667 shares. The Plan was approved by the Board and stockholders. The purpose of the Plan is to grant stock and options to purchase shares of Common Stock, and other incentive awards, to our employees, directors, and key consultants. On July 24, 2025, stockholders voted to increase the maximum number of shares of Common Stock that may be issued pursuant to awards granted under the Plan by 23,333 shares. On August 14, 2026, stockholders voted (i) to increase the maximum number of shares of Common Stock that may be issued pursuant to awards granted under the Plan by 140,000 shares and (ii) to adopt an evergreen provision providing for an automatic annual increase in the shares of Common Stock available for future awards under the Plan. Pursuant to the increases, the maximum number of shares of Common Stock that may be issued pursuant to awards granted under the Plan is 170,000 shares. The shares of Common Stock underlying cancelled and forfeited awards issued under the Plan may again become available for grant under the Plan. As of September 30, 2026, there were 23,902 stock options outstanding and 1,037 shares of restricted stock granted in prior years under the Plan, which left 145,061 shares available for grant under the Plan. The following table summarizes stock option transactions for the nine months ended September 30, 2026:

  

    Nine Months Ended September 30, 2026  
    Number of     Weighted Average  
    Options     Exercise Price  
Options outstanding at December 31, 2025     23,902     $ 105.81  
Granted     —       —  
Forfeited/cancelled     —       —  
Exercised     —       —  
Options outstanding at September 30, 2026     23,902     $ 105.81  
Options exercisable at September 30, 2026     22,169     $ 111.28  

 

The weighted average remaining contractual life of all options outstanding, and all options vested and exercisable as of September 30, 2026 was approximately 8.6 years. Furthermore, the aggregate intrinsic value of all options outstanding and all options vested and exercisable as of September 30, 2026 was $0, in each case based on the fair value of the Common Stock on September 30, 2026.

 

The total fair value of options that vested during the nine months ended September 30, 2026 and 2025, was $138,000 and $386,000, respectively, and is included in selling, general and administrative expense in the accompanying unaudited condensed statements of operations. As of September 30, 2026, 22,169 stock options were vested and exercisable and unvested compensation expense amounted to approximately $56,000.

 

Options outstanding as of September 30, 2026 are exercisable as follows:

  

      Stock Options Exercisable as of September 30, 2026  

Range of

Exercise Price

   

Number

Outstanding

   

Weighted Average

Remaining Contractual Life (Years)

   

Weighted Average

Exercise Price

 
$ 33.25       19,500       8.9     $ 33.25  
  52.75       700       7.7       52.75  
  262.50       667       6.6       262.50  
  637.50       667       6.3       637.50  
  1,860.00       635       5.8       1,860.00  
          22,169               111.28